JP2024504926A5 - - Google Patents
Info
- Publication number
- JP2024504926A5 JP2024504926A5 JP2023541722A JP2023541722A JP2024504926A5 JP 2024504926 A5 JP2024504926 A5 JP 2024504926A5 JP 2023541722 A JP2023541722 A JP 2023541722A JP 2023541722 A JP2023541722 A JP 2023541722A JP 2024504926 A5 JP2024504926 A5 JP 2024504926A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- car
- tumor
- receptor
- dnase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135438P | 2021-01-08 | 2021-01-08 | |
| US63/135,438 | 2021-01-08 | ||
| US202163148304P | 2021-02-11 | 2021-02-11 | |
| US63/148,304 | 2021-02-11 | ||
| PCT/US2022/011648 WO2022150609A1 (en) | 2021-01-08 | 2022-01-07 | Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504926A JP2024504926A (ja) | 2024-02-02 |
| JP2024504926A5 true JP2024504926A5 (https=) | 2025-01-15 |
Family
ID=82358327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541722A Pending JP2024504926A (ja) | 2021-01-08 | 2022-01-07 | がんの処置のためのデオキシリボヌクレアーゼ酵素と細胞療法の組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240050476A1 (https=) |
| EP (1) | EP4274585A4 (https=) |
| JP (1) | JP2024504926A (https=) |
| CA (1) | CA3203945A1 (https=) |
| WO (1) | WO2022150609A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3219838A1 (en) * | 2021-05-21 | 2022-11-24 | Dmitry Dmitrievich Genkin | Immunomodulation of tumor microenvironment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017302668B9 (en) * | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| AU2019209770B2 (en) * | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| US12258597B2 (en) * | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| US11058724B2 (en) * | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| CA3219838A1 (en) * | 2021-05-21 | 2022-11-24 | Dmitry Dmitrievich Genkin | Immunomodulation of tumor microenvironment |
-
2022
- 2022-01-07 JP JP2023541722A patent/JP2024504926A/ja active Pending
- 2022-01-07 WO PCT/US2022/011648 patent/WO2022150609A1/en not_active Ceased
- 2022-01-07 US US18/271,453 patent/US20240050476A1/en active Pending
- 2022-01-07 CA CA3203945A patent/CA3203945A1/en active Pending
- 2022-01-07 EP EP22737186.1A patent/EP4274585A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523204A5 (https=) | ||
| Shi et al. | Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment | |
| JP2024074801A5 (https=) | ||
| JP2023524047A5 (https=) | ||
| RU2020127887A (ru) | Полипептиды транспозазы и их применение | |
| JP2024520676A5 (https=) | ||
| RU2020120411A (ru) | Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения | |
| JP2016117766A5 (https=) | ||
| JP2023501722A5 (https=) | ||
| JP2021525731A5 (https=) | ||
| JP2021502104A5 (https=) | ||
| JP2021525509A5 (https=) | ||
| Ponterio et al. | Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture | |
| EP3578570A1 (en) | Multifunctional protein | |
| JP2022545167A5 (https=) | ||
| WO2014138314A1 (en) | Oncolytic virus | |
| JP2021500932A5 (https=) | ||
| JP2015530359A5 (https=) | ||
| JP2024521472A5 (https=) | ||
| JP2016519651A5 (https=) | ||
| Zhu et al. | Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F (ab′) 2 for efficient lysis of p185HER2 overexpressing tumor cells | |
| JP2021522208A5 (https=) | ||
| JP2024509095A5 (https=) | ||
| JP2024504926A5 (https=) | ||
| ES2965437T3 (es) | Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas |